6833 — Sinco Pharmaceuticals Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapValue Trap

Market Cap
HK$498.06m
Enterprise Value
HK$296.26m
Revenue
CNY2.54bn

Annual income statement for Sinco Pharmaceuticals Holdings, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	R2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,176	2,050	2,024	2,272	2,540
Cost of Revenue
Gross Profit	220	274	365	306	323
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,113	1,905	1,828	2,154	2,426
Operating Profit	63	145	197	118	114
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	43	136	167	99.3	99.9
Provision for Income Taxes
Net Income After Taxes	23.6	118	135	69.5	42.4
Minority Interest
Net Income Before Extraordinary Items
Net Income	23.6	118	135	69.5	42.4
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	23.6	118	135	69.5	42.4
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.014	0.07	0.078	0.034	0.021
Dividends per Share